Newsroom

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.
May 7, 2019 5:32 pm

Home

Form Search Home

   
Subscribe for Updates
Components
TITLE
Latest Press Releases
Latest News
Press Release | July 30, 2020
Vertex Reports Second-Quarter 2020 Financial Results
READ MORE
Press Release | July 20, 2020
Positive Phase 3 Study Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function Mutation
READ MORE
Press Release | July 16, 2020
Vertex to Announce Second-Quarter 2020 Financial Results on July 30
READ MORE
Press Release | June 30, 2020
Vertex Announces Expansion of Reimbursement Agreement With NHS England to Include KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor)
READ MORE
Media Library Title
Media Library
MEDIA
Corporate Brochure

At Vertex, we are relentless. Bringing together the brightest minds, investing in science and taking smart risks, we strike at the core of serious diseases.

8851981 KB
Vertex Corporate Brochure_FINAL.pdf8851981 KB
Brochures
Vertex Logo

Vertex Logo

1560045 KB
vertexlogoR_rgb.pdf1560045 KB
Images, Logos
Reshma Kewalramani, M.D.

President and CEO

11520832 KB
Reshma_0.pdf11520832 KB
Headshots
Infographic - Research & Development

At Vertex, we are relentless. Bringing together the brightest minds, investing in science and taking smart risks, we strike at the core of serious diseases.

489851 KB
RD Infographic_sheet FINAL.pdf489851 KB
Brochures